AtheroNova Inc.

IRVINE, Calif., May 9, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that its Russian licensing partner CardioNova has received written notification ... read more

IRVINE, Calif., April 15, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that John J.P. Kastelein, MD, PhD, Professor of Medicine at the ... read more

In the news release, AtheroNova Adds New Medical Advisor, issued April 15, 2013 by AtheroNova Inc. over PR Newswire, we are advised by the company that updates have been made. The complete, corrected release follows: Noted Atherosclerosis Researcher Joins AtheroNova Team Dr. John Kastelein Appointed Co-Principal Investigator ... read more

IRVINE, Calif., April 15, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that John Kastelein, MD, Ph.D., Chairman of the department of vascular medicine ... read more

IRVINE, Calif., April 11, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Stephen Nicholls, M.B.B.S., PhD., Heart Disease Theme leader at the South ... read more

IRVINE, CA--(Marketwire - January 29, 2013) - AtheroNova Inc. (OTCQB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced the launch ... read more

IRVINE, Calif., Jan. 17, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that its CEO, Thomas W. Gardner, will present at "NINE"; Noble Financial ... read more

IRVINE, Calif., Jan. 8, 2013 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Joan E. Shaw, MT (ASCP), SCC has joined the Company ... read more

IRVINE, Calif., Dec. 18, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Mark K. Wedel, MD, JD has joined the Company as ... read more

IRVINE, Calif., Dec. 18, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that Mark K. Wedel, MD, JD has joined the Company as ... read more

IRVINE, CA -- (Marketwire) -- 08/24/11 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, will be a presenting company at the Rodman & Renshaw 13th Annual Healthcare and Global Investment Conference to be held in ... read more

IRVINE, CA -- (Marketwire) -- 06/13/11 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that Balbir (Bal) S. Brar, PhD, DVM, has been appointed Senior Vice President of Drug Development. "Dr. Brar's extensive experience of ... read more

IRVINE, CA -- (Marketwire) -- 05/16/11 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that Stephen J. Nicholls, MBBS, PhD, Medical Director of Intravascular Ultrasound and Angiography Core Laboratories at Cleveland Clinic and Clinical ... read more

IRVINE, CA -- (Marketwire) -- 05/03/11 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, will pursue an additional indication to address significant unmet needs in stroke prevention with a compound to treat Intracranial atherosclerosis disease ... read more

IRVINE, CA -- (Marketwire) -- 04/11/11 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that Paul S. Nassif, M.D., FACS and Founder of Spalding Drive Cosmetic Surgery and Dermatology, has been named to the ... read more

IRVINE, CA -- (Marketwire) -- 03/01/11 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, addressed a study presented at the American Stroke Association (ASA) conference that found a dramatic statistically significant increase in ischemic stroke ... read more

IRVINE, CA -- (Marketwire) -- 02/22/11 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that the Company's second round preclinical atherosclerotic plaque regression study has commenced at The David Geffen School of Medicine at UCLA. The ... read more

IRVINE, CA -- (Marketwire) -- 01/10/11 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, today announced the filing of a patent application for the use of the Company's delipidization technology in the treatment of obesity. These ... read more

IRVINE, CA -- (Marketwire) -- 11/17/10 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a novel compounds biotech company focused on research and development to regress atherosclerotic plaque, announced that Paul DiPerna, CTO and Founder of Tandem Diabetes Care, has been named to the Board of Directors of AtheroNova Inc. "As ... read more

IRVINE, CA -- (Marketwire) -- 11/09/10 -- AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that the Company has signed a research agreement for its second phase of a pre-clinical laboratory animal study to be ... read more